Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance - PubMed (original) (raw)

Randomized Controlled Trial

Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance

James C M Brust et al. AIDS Res Hum Retroviruses. 2011 May.

Abstract

Direct observation of antiretroviral therapy (DOT) can increase adherence rates in HIV-infected substance users, but whether this affects the development of antiretroviral drug resistance has not been fully explored. We conducted a 24-week randomized controlled trial of methadone clinic-based antiretroviral DOT compared with treatment as usual (TAU) among antiretroviral-experienced substance users. To examine the development of new resistance mutations, we identified all participants with an amplifiable resistance test at both baseline and either week 8 or week 24. We compared the development of new drug resistance mutations between participants in the two arms of the trial. Among the 77 participants enrolled in the parent trial, antiretroviral DOT was efficacious for improving adherence and decreasing HIV viral load. Twenty-one participants had a detectable HIV viral load at both baseline and a second time point. Of these, nine developed new drug resistance mutations not seen at baseline (three in the DOT arm and six in the TAU arm; p = 0.27). Overall, five subjects in the TAU arm developed major mutations correlating with their current antiretroviral regimen, while no subjects in the DOT arm developed such mutations. Direct observation of antiretroviral therapy was associated with improved adherence and viral suppression among methadone maintained HIV-infected substance users, but was not associated with an increase in the development of antiretroviral drug resistance. DOT should be considered for substance users attending methadone maintenance clinics who are at high risk of nonadherence.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Flowchart of subjects included in the study analysis. GT, genotypic resistance test.

References

    1. May M. Sterne JA. Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS. 2007;21:1185–1197. -PMC -PubMed
    1. Walensky RP. Paltiel AD. Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–19. -PubMed
    1. Braitstein P. Brinkhof MW. Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet. 2006;367:817–824. -PubMed
    1. Bangsberg DR. Hecht FM. Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366. -PubMed
    1. Low-Beer S. Yip B. O'Shaughnessy MV. Hogg RS. Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–361. -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources